Rabeprazole
Sold as Pariet, Rabemed, Acifix, Baprez otc, Baprez ec, Rabeprazole SPEC, Rabaci, Maklorab, Ulcopraz, Aciphex
2-[[4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl]methylsulfinyl]-1H-benzimidazole
Drag to rotate. Structure from PubChem CID 5029.
Background
Registration
- Applicants
- 7
- Registrations
- 18
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Janssen Pharmaceutica (Pty) Ltd2 of 4 cancelled | Pariet, Aciphex | 10 mg, 20 mg | 320614, 330206, A390468, A390469 | Not determined | None |
| Sandoz South Africa (Pty) Ltd | Rabemed | 10, 20 | 440597, 440598 | Not determined | None |
| Abex Pharmaceutica (Pty) Ltd | Acifix | 10, 20 | 471283, 471284 | Not determined | None |
| Ranbaxy Pharmaceutical (Pty) Ltd | Baprez otc, Baprez ec | 20 | 481095, 481096 | Not determined | None |
| Specpharm (Pty) Ltd | Rabeprazole SPEC | 10, 20 | 490955, 490956 | Not determined | None |
| Astral Pharma (Pty) Ltd | Rabaci | 10, 20 | 509022, 509023 | Not determined | None |
| Macleods Pharmaceuticals SA (Pty) Ltd | Maklorab, Ulcopraz | 10, 20 | 560621, 560622, 560623.621, 560624.622 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Pariet 20 MG EACH TABLET CONTAINS RABEPRAZOLE SODIUM 20,0 mg | 20 mg | 32061432/11.4.3/0614 | Registered | Not determined | None |
| Pariet 10 MG EACH TABLET CONTAINS RABEPRAZOLE SODIUM 10,0 mg | 10 mg | 33020633/11.4.3/0206 | Registered | Not determined | None |
| Rabemed 10 EACH TABLET CONTAINS RABEPRAZOLE SODIUM 10,0 mg | 10 | 44059744/11.4.3/0597 | Registered | Not determined | None |
| Rabemed 20 EACH TABLET CONTAINS RABEPRAZOLE SODIUM 20,0 mg | 20 | 44059844/11.4.3/0598 | Registered | Not determined | None |
| Acifix 10 Each tablet contains :10,0 mg RABEPRAZOLE SODIUM EQUIVALENT TO RABEPRAZOLE 9,40 mg | 10 | 47128347/11.4.3/1283 | Registered | Not determined | None |
| Acifix 20 EACH TABLET CONTAINS: 20,0 mg RABEPRAZOLE SODIUM EQUIVALENT TO RABEPRAZOLE 18,80 mg | 20 | 47128447/11.4.3/1284 | Registered | Not determined | None |
| Baprez otc Each centeric coated tablet contains: Rabeprazole sodium equivalent to Rabeprazole 9,42 mg | Not listed | 48109548/11.4.3/1095 | Registered | Not determined | None |
| Baprez 20 ec Each enteric coated tablet contains: Rabeprazole sodium equivalent to rabeprazole 18,85 mg | 20 | 48109648/11.4.3/1096 | Registered | Not determined | None |
| Rabeprazole 10 SPEC Each tablet contains 10,0 mg RABEPRAZOLE SODIUM EQUIVALENT TO RABEPRAZOLE 9,42 mg | 10 | 49095549/11.4.3/0955 | Registered | Not determined | None |
| Rabeprazole 20 SPEC Each tablet contains 20,0 mg RABEPRAZOLE SODIUM EQUIVALENT TO RABEPRAZOLE 18,85 mg | 20 | 49095649/11.4.3/0956 | Registered | Not determined | None |
| Rabaci 10 Each tablet contains 10,0 mg RABEPRAZOLE SODIUM EQUIVALENT TO RABEPRAZOLE 9,40 mg | 10 | 50902250/11.4.3/9022 | Registered | Not determined | None |
| Rabaci 20 Each tablet contains 20,0 mg RABEPRAZOLE SODIUM EQUIVALENT TO RABEPRAZOLE 18,80 mg | 20 | 50902350/11.4.3/9023 | Registered | Not determined | None |
| Maklorab 10 EACH TABLET CONTAINS RABEPRAZOLE SODIUM 10,0 mg | 10 | 56062156/11.4.3/0621 | Registered | Not determined | None |
| Maklorab 20 EACH TABLET CONTAINS RABEPRAZOLE SODIUM 20,0 mg | 20 | 56062256/11.4.3/0622 | Registered | Not determined | None |
| Ulcopraz 10 EACH TABLET CONTAINS RABEPRAZOLE SODIUM 10,0 mg | 10 | 560623.62156/11.4.3/0623.621 | Registered | Not determined | None |
| Ulcopraz 20 EACH TABLET CONTAINS RABEPRAZOLE SODIUM 20,0 mg | 20 | 560624.62256/11.4.3/0624.622 | Registered | Not determined | None |
| Aciphex 10 EACH TABLET CONTAINS RABEPRAZOLE SODIUM 10,0 mg | 10 | A390468A39/11.4.3/0468 | Cancelled | Not determined | None |
| Aciphex 20 EACH TABLET CONTAINS RABEPRAZOLE SODIUM 20,0 mg | 20 | A390469A39/11.4.3/0469 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Rabeprazole
- except when intended for the temporary short term relief of heartburn and hyperacidity, subject to-
- maximum daily dose of 10 milligrams;
- maximum treatment period of 14 days. (S2)
Consolidated Schedules 06 July 2026, lines 7702 to 7707
S2: Rabeprazole
- when intended for the temporary short term relief of heartburn and hyperacidity, subject to-
- maximum daily dose of 10 milligrams;
- maximum treatment period of 14 days. (S4)
Consolidated Schedules 06 July 2026, lines 2619 to 2623
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.